Poly Medicure (NSE:POLYMED) disclosed the outcome of its Board of Directors meeting held on 7 August 2026 at Jaipur Marriott Hotel, covering unaudited Q1 FY27 financial results, an ESOP grant and allotment, reappointment of cost auditors, and the resignation of its Deputy Company Secretary.
Key Highlights
- Standalone revenue from operations for Q1 FY27 (quarter ended 30 June 2026) stood at Rs 43,109.95 lacs, up from Rs 38,404.67 lacs in Q1 FY26.
- Standalone profit after tax for Q1 FY27 was Rs 8,812.33 lacs, compared with Rs 8,792.89 lacs in the corresponding quarter of the prior year.
- The Nomination and Remuneration Committee approved the grant of 1,476 stock options and the allotment of 1,975 equity shares of face value Rs 5 each under the Poly Medicure Employee Stock Option Scheme 2020.
- Mr. Ravi Prakash, Deputy Company Secretary and Compliance Officer (Key Managerial Personnel), tendered his resignation on 21 July 2026 and will be relieved effective close of business on 10 August 2026.
About the Company
Poly Medicure (NSE:POLYMED), headquartered in New Delhi with manufacturing plants in Ballabgarh and Faridabad, Haryana, is engaged in the design and manufacture of single-use medical devices including IV sets, blood administration sets, catheters, and dialysis products. The company sells its products across more than 100 countries and operates foreign subsidiaries including Polymed Brazil LTDA, placing it within India's medical devices sector.
Announcement in Detail
The board meeting, held between 1:15 PM and 2:20 PM on 7 August 2026, approved unaudited standalone and consolidated financial results for Q1 FY27. On a consolidated basis, revenue from operations reached Rs 52,537.55 lacs for the quarter ended 30 June 2026, against Rs 40,321.07 lacs in Q1 FY26. Consolidated profit after tax was Rs 8,527.43 lacs versus Rs 9,308.29 lacs a year earlier.
The ESOP allotment of 1,975 equity shares increased the paid-up equity share capital to Rs 50,68,07,325, comprising 10,13,61,465 shares of face value Rs 5 each, from Rs 50,67,97,450 previously. M/s Jai Prakash and Company was reappointed as cost auditors for FY 2026-27. The filing also noted that Polymed Brazil LTDA acquired 100% equity in Medyneo Comercio De Produtos Para Saude LTDA for a total consideration of Rs 34.08 lacs, effective 29 April 2026.
Impact on Investors
Investors will note that the ESOP allotment of 1,975 shares represents a marginal increase in outstanding equity, with paid-up capital rising by Rs 9,875 in face-value terms. The disclosed terms indicate this dilution is negligible relative to the total share count of over 10.13 crore shares. Shareholders will observe that consolidated profit after tax declined to Rs 8,527.43 lacs in Q1 FY27 from Rs 9,308.29 lacs in Q1 FY26, even as consolidated revenue from operations grew by approximately 30% year-on-year.
The filing shows that Mr. Ravi Prakash's departure from the role of Compliance Officer constitutes a change in Key Managerial Personnel. Investors will note that SEBI's Listing Obligations and Disclosure Requirements Regulations require timely appointment of a replacement Compliance Officer, and the company has not yet disclosed a successor in this filing.
Sector / Market Context
India's medical devices industry has been a focus area under government policy, with the Production Linked Incentive scheme for medical devices attracting investments from domestic manufacturers. According to the Indian Medical Devices Industry Association, the domestic market has expanded steadily as hospitals deepen their procurement of single-use products. Poly Medicure's export-oriented model, serving over 100 countries, positions it within a segment where global demand for cost-competitive, quality-certified disposable medical devices from India has been a documented trend in sector filings and FICCI healthcare reports.